EMA Authorised: Jivi (Damoctocog alfa pegol) — Bayer AG

View source ↗

Summary

The European Medicines Agency has authorised Bayer's Jivi (damoctocog alfa pegol) for the treatment of Hemophilia A in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Jivi

Snippet

Status: Authorised. Therapeutic area: Hemophilia A. MAH: Bayer AG. Decision date: 12/08/2025